Dexcom cuts guidance as Q2 revenue falls short of estimates; shares slump

Investing.com -- Dexcom cut its guidance Thursday after reporting second-quarter revenue fell short of estimates as the diabetes management flagged weaker execution of key strategies.

DexCom Inc (NASDAQ: DXCM) fell more than 34% in aftermarket hours following the report.

The company now expects revenue of approximately $4.00B to $4.05B, down from prior guidance of $4.20B to $4.35B.

"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," the company said

The company reported Q2 earnings $0.43 per share on revenue of $1.00 billion, compared with estimates of $0.39 on revenue of $1.04B.

For Q3, revenue was guided in a range of $ $975M to $1.00B, missing analyst estimates of $1.15B.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Pfizer lung cancer drug misses survival goal in Phase 3 trial